BCG Versus Mitomycin C—A Systematic Review-Reference-Cited by-同舟云学术

BCG Versus Mitomycin C—A Systematic Review

Published:2019-10-24 Issue: Volume: Page:209-220
ISSN:
Container-title:Management of Non-Muscle Invasive Bladder Cancer
language:
Short-container-title:

Author:

Goonewardene Sanchia S.,Persad Raj,Motiwala Hanif,Albala David

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/978-3-030-28646-0_41

Reference22 articles.

1. Badalato GM, Hruby G, Razmjoo M, McKiernan JM. Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG? Can J Urol. 2011;18(5):5890–5.

2. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007;52(4):1123–9.

3. Gårdmark T, Jahnson S, Wahlquist R, Wijkström H, Malmström PU. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and Bacillus Calmette-Guérin in patients with high-risk bladder cancer. BJU Int. 2007;99(4):817–20. Epub 2007 Jan 22.

4. Isbarn H, Budäus L, Pichlmeier U, Conrad S, Huland H, Friedrich MG. Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or Bacillus Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder. Urologe A. 2008;47(5):608–15.

5. Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group. Long-term efficacy of maintenance Bacillus Calmette-Guérin versus instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised Finn Bladder I study with a 20-year follow-up. Eur Urol. 2009;56(2):260–5.